Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRVJ1A)

• Drug Name: Corus 1030 Drug Info
• Synonyms: Inhaled Lidocaine

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Discontinued in Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMRVJ1A

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.7 (SCN9A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
XEN-402	DMR69CG	Osteoarthritis	FA00-FA05	Phase 2	[3]
PF-05089771	DMD74BJ	Chronic pain	MG30	Phase 2	[4]
BIIB074	DMLV1ET	Bipolar disorder	6A60	Phase 2	[5]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[5]
BIIB095	DMUC6EP	Pain	MG30-MG3Z	Phase 1	[5]
GDC0310	DMUNFEP	Chronic pain	MG30	Phase 1	[6]
DSP-3905	DMYHU24	Neuropathic pain	8E43.0	Phase 1	[5]
PF-05241328	DM2NTBL	Pain	MG30-MG3Z	Phase 1	[7]
DWJ-208	DMQKDJZ	Cancer related pain	MG30	Phase 1	[5]
RG7893	DM1R4MQ	Pain	MG30-MG3Z	Phase 1	[8]

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.8 (SCN10A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[9]
Ropivacaine	DMSPJG2	Anaesthesia	9A78.6	Approved	[10]
Bupivacaine	DM4PRFC	Anaesthesia	9A78.6	Approved	[10]
Tiapride	DMN6CAG	Alcohol dependence	6C40.2	Approved	[11]
Tetracaine	DM9J6C2	Spinal anesthesia	MB40.3	Approved	[12]
Proparacaine	DMLS39E	Anaesthesia	9A78.6	Approved	[10]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[13]
VX-150	DMGDB21	Neuropathic pain	8E43.0	Phase 2	[6]
DSP-2230	DM0WTMD	Neuropathic pain	8E43.0	Phase 1	[5]
PF-01247324	DM93LMS	Pain	MG30-MG3Z	Phase 1	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.7 (SCN9A)	TT4G2JS	SCN9A_HUMAN	Modulator	[2]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017745)
• [2] Differential modulation of Nav1.7 and Nav1.8 peripheral nerve sodium channels by the local anesthetic lidocaine. Br J Pharmacol. 2004 Jun;142(3):576-84.
• [3] Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012 Jan;153(1):80-5.
• [4] Primary erythromelalgia: a review. Orphanet J Rare Dis. 2015 Sep 30;10:127.
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9.
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041740)
• [9] Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [11] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [12] Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
• [13] Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
• [14] Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.